TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06885931: Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System

Sponsor: Amber Therapeutics Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 86 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,540,400

Rescue Site Savings

+$4,316,000

Unlock Full NCT06885931 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06885931 Rescue Dossier →